European drug market entries 2015 with new mechanisms of action
- Titus W P van den Heuvel, scientistA,
- Adam F Cohen, professor of clinical pharmacologyB and
- Robert Rissmann, associate professor of clinical pharmacologyC⇑
- ALeiden University Medical Centre, Leiden, the Netherlands
- BLeiden University Medical Centre, Leiden, the Netherlands and CEO, Centre for Human Drug Research, Leiden, the Netherlands
- CLeiden University Medical Centre, Leiden, the Netherlands and director of education, Centre for Human Drug Research, Leiden, the Netherlands
- Address for correspondence: R Rissmann, Centre for Human Drug Research. Zernikedreef 8, 2333CL Leiden, The Netherlands. Email: rrissmann{at}chdr.nl
ABSTRACT
In this article, we consider the new drugs approved for the European market in 2015. We present a summary of the new mechanisms of action introduced and highlight three new mechanisms of action with a potentially high future impact: PCSK9 inhibition (alirocumab (Praluent®) and evolocumab (Repatha®)) for hypercholesterolaemia, neprilysin inhibition (sacubitril in combination with valsartan (Entresto®)) for heart failure, and interleukin-5 inhibition (mepolizumab (Nucala®)) for asthma.
- © Royal College of Physicians 2016. All rights reserved.
